scholarly journals Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer—A pilot study

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0175589 ◽  
Author(s):  
Katsuyuki Shirai ◽  
Motohiro Kawashima ◽  
Jun-ichi Saitoh ◽  
Takanori Abe ◽  
Kyohei Fukata ◽  
...  
2019 ◽  
Vol 110 (2) ◽  
pp. 734-741 ◽  
Author(s):  
Kazuhiko Hayashi ◽  
Naoyoshi Yamamoto ◽  
Mio Nakajima ◽  
Akihiro Nomoto ◽  
Hiroshi Tsuji ◽  
...  

Lung Cancer ◽  
2009 ◽  
Vol 64 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Toshio Sugane ◽  
Masayuki Baba ◽  
Reiko Imai ◽  
Mio Nakajima ◽  
Naoyoshi Yamamoto ◽  
...  

Author(s):  
Cathy Fleming ◽  
Ronan McDermott ◽  
Serena O’Keeffe ◽  
Mary Dunne ◽  
John G. Armstrong ◽  
...  

Abstract Aim: This work compares dose-volume constraints (DVCs) and tumour control predictions based on the average intensity projection (AVIP) to those on each phase of the four-dimensional computed tomography. Materials and methods: In this prospective study plans generated on an AVIP for nine patients with locally advanced non-small-cell lung cancer were recalculated on each phase. Dose-volume histogram (DVH) metrics extracted and tumour control probabilities (TCP) were calculated. These were evaluated by Bland–Altman analysis and Pearson Correlation. Results: The largest difference between clinical target volume (CTV) on the individual phases and the internal CTV (iCTV) on the AVIP was seen for the smallest volume. For the planning target volume, the mean of each metric across all phases is well represented by the AVIP value. For most patients, TCPs from individual phases are representative of that on the AVIP. Organ at risk metrics from the AVIP are similar to those seen across all phases. Findings: Utilising traditional DVH metrics on an AVIP is generally valid, however, additional investigation may be required for small target volumes in combination with large motion as the differences between the values on the AVIP and any given phase may be significant.


2019 ◽  
Vol 40 (1) ◽  
pp. 379-386 ◽  
Author(s):  
MAKOTO ANZAI ◽  
NAOYOSHI YAMAMOTO ◽  
KAZUHIKO HAYASHI ◽  
MIO NAKAJIMA ◽  
AKIHIRO NOMOTO ◽  
...  

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S132
Author(s):  
Tadaaki Miyamoto ◽  
Masayuki Baba ◽  
Toshiyuki Sugawara ◽  
Naoyoshi Yamamoto ◽  
Masashi Koto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document